Soluble amyloid beta oligomer (Aβ oligomer)

Soluble amyloid beta oligomers are assemblies of the amyloid-beta peptide, ranging from dimers up to larger multi-meric species that remain dispersed in solution rather than aggregated into insoluble plaques. These oligomers are considered the most neurotoxic conformers in Alzheimer's disease, responsible for synaptic dysfunction, impaired plasticity, abnormal signaling, and loss of neuronal function. They are generated via the proteolytic cleavage of amyloid precursor protein (APP) followed by self-assembly, a process influenced by factors such as lipid rafts, gangliosides, and transition metal ions. The presence and level of soluble oligomers correlate strongly with cognitive decline and disease progression, distinguishing them from larger fibrillar plaques which may be less biologically active. Therapeutic strategies in development aim to neutralize, sequester, prevent formation, or promote the clearance of these toxic oligomeric species. Their heterogeneity and transient nature pose analytical and clinical challenges, but they remain a central, validated target for disease-modifying interventions in Alzheimer's disease and potentially other neurodegenerative disorders.

Other names

Amyloid beta oligomerSoluble Aβ oligomerAmyloid-beta peptide oligomerOligomeric AβAβ oligomersSoluble Abeta oligomersPrefibrillar amyloid beta

Neutralization of Aβ oligomers (immunotherapy); Prevention of oligomer formation (aggregation inhibitors, secretase modulators); Promotion of Aβ clearance (enhanced transport across BBB, enzymatic degradation); Stabilization or sequestration of non-toxic forms; Inhibition of oligomer-induced synaptotoxicity